Thomas Leggett serves as Chief Financial Officer at Stoke Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering genetic medicines to treat severe neurological disorders through RNA modulation. Since joining in July 2020, he has spearheaded the company's financial operations, including strategic capital raises exceeding $300 million, budgeting, forecasting, and investor relations. Under his leadership, Stoke has advanced its pipeline, including the ongoing development of STK-001 for Dravet syndrome, while maintaining robust financial discipline amid biotech market volatility. Prior to Stoke, Leggett was CFO at bluebird bio from 2016 to 2020, where he managed finances through rapid expansion, multiple equity offerings, and key partnerships. He previously held the role of Senior Vice President and CFO at Cubist Pharmaceuticals from 2011 to 2014, orchestrating the company's $9.5 billion acquisition by Merck & Co. Earlier in his career, spanning over two decades at Genzyme Corporation (now part of Sanofi), he progressed through senior finance roles, contributing to commercial launches and global operations. With an MBA from Harvard Business School and a BA from Dartmouth College, Leggett brings more than 25 years of expertise in biotechnology finance. His achievements include navigating complex financings, M&A transactions, and regulatory milestones, positioning him as a pivotal leader in driving sustainable growth for innovative therapeutics companies like Stoke.